Syngene International Limited SYNGENE NIFTY_SMALLNSEPHARMA
Company Overview
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Why Investors Should Care
Operating margin of 15.4% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.09.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹3,610.70 Cr (+2.8% YoY); net profit ₹316.70 Cr.
- Trailing 12 Months Year-on-year growth — revenue +2.8%, earnings -36.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.4%, profit CAGR -12.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.44% |
| 1 Year: | 2.79% |
Compounded Profit Growth
| 5 Years: | -11.98% |
| 1 Year: | -36.17% |
Stock Price Performance
| 1 Year: | -38.87% |
| 6 Months: | -0.75% |
| 3 Months: | -10.71% |
| 1 Month: | -1.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.60 · Neutral
P/E of 50.27 is above the sector median of 41.64 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 50.3.
- Earnings shrank at -12.0% CAGR over 5 years.
- Trading 41.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SYNGENE Syngene International Limited NIFTY_SMALLNSEPHARMA | 395.60 | 50.27 | ₹15,940.28 Cr | 0.31% | 8.28% | 6.54% | 5.44% | -11.98% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 994.00 Cr | 808.00 Cr | 910.00 Cr | 854.00 Cr | 917.00 Cr | 790.00 Cr | 891.00 Cr | 943.70 Cr | 1,018.00 Cr | 874.50 Cr | 911.00 Cr | 917.10 Cr | 1,036.50 Cr | 736.00 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | 237.40 Cr | 235.00 Cr | 217.60 Cr | - | 229.40 Cr | 233.10 Cr | 173.40 Cr |
| Gross Profit | - | - | - | - | - | - | - | 706.30 Cr | 783.00 Cr | 656.90 Cr | - | 687.70 Cr | 803.40 Cr | 562.60 Cr |
| Operating Expenses | 680.00 Cr | 596.00 Cr | 656.00 Cr | 622.00 Cr | 600.00 Cr | 620.00 Cr | 646.00 Cr | 533.10 Cr | 540.90 Cr | 556.90 Cr | 711.00 Cr | 569.00 Cr | 590.40 Cr | 533.90 Cr |
| Operating Income | 218.00 Cr | 110.00 Cr | 149.00 Cr | 124.00 Cr | 206.00 Cr | 63.00 Cr | 134.00 Cr | 173.20 Cr | 242.10 Cr | 100.00 Cr | 84.00 Cr | 118.70 Cr | 213.00 Cr | 28.70 Cr |
| EBITDA | 314.00 Cr | 212.00 Cr | 254.00 Cr | 232.00 Cr | 317.00 Cr | 170.00 Cr | 245.00 Cr | 301.90 Cr | 362.50 Cr | 224.10 Cr | 200.00 Cr | 154.00 Cr | 319.60 Cr | 102.60 Cr |
| Interest Expense | 10.00 Cr | 10.00 Cr | 13.00 Cr | 11.00 Cr | 13.00 Cr | 12.00 Cr | 13.00 Cr | 12.40 Cr | 15.90 Cr | 11.60 Cr | 13.00 Cr | 11.90 Cr | 12.10 Cr | 9.60 Cr |
| Pretax Income | 231.00 Cr | 123.00 Cr | 151.00 Cr | 138.00 Cr | 209.00 Cr | 101.00 Cr | 137.00 Cr | 180.80 Cr | 240.50 Cr | 101.30 Cr | 85.00 Cr | 28.40 Cr | 196.00 Cr | -19.20 Cr |
| Tax Provision | 53.13 Cr | 29.52 Cr | 34.73 Cr | 26.22 Cr | 20.90 Cr | 25.25 Cr | 31.51 Cr | 49.70 Cr | 57.20 Cr | 14.60 Cr | 17.85 Cr | 13.40 Cr | 48.10 Cr | -10.20 Cr |
| Net Income | 179.00 Cr | 93.00 Cr | 116.00 Cr | 112.00 Cr | 189.00 Cr | 76.00 Cr | 106.00 Cr | 131.10 Cr | 183.30 Cr | 86.70 Cr | 67.00 Cr | 15.00 Cr | 147.90 Cr | -9.00 Cr |
| Diluted EPS | 4.45 | 2.32 | 2.90 | 2.77 | 4.69 | 1.88 | 2.64 | 3.26 | 4.56 | 2.15 | 1.67 | 0.37 | 3.67 | -0.22 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,423.00 Cr | 1,826.00 Cr | 2,012.00 Cr | 2,184.00 Cr | - | 3,080.20 Cr | 3,369.50 Cr | 3,512.80 Cr | 3,610.70 Cr |
| Cost of Revenue | - | - | - | - | - | 860.20 Cr | 930.20 Cr | 942.50 Cr | 918.60 Cr |
| Gross Profit | - | - | - | - | - | 2,220.00 Cr | 2,439.30 Cr | 2,570.30 Cr | 2,692.10 Cr |
| Operating Expenses | 949.00 Cr | 1,289.00 Cr | 1,394.00 Cr | 1,507.00 Cr | - | 1,601.80 Cr | 1,792.20 Cr | 1,956.90 Cr | 2,134.80 Cr |
| Operating Income | 343.00 Cr | 373.00 Cr | 399.00 Cr | 404.00 Cr | - | 618.20 Cr | 647.10 Cr | 613.40 Cr | 557.30 Cr |
| EBITDA | 474.00 Cr | 537.00 Cr | 618.00 Cr | 678.00 Cr | - | 994.60 Cr | 1,091.80 Cr | 1,141.70 Cr | 908.60 Cr |
| Interest Expense | 23.00 Cr | 32.00 Cr | 35.00 Cr | 28.00 Cr | - | 34.50 Cr | 45.10 Cr | 49.20 Cr | 44.80 Cr |
| Pretax Income | 372.00 Cr | 415.00 Cr | 517.00 Cr | 469.00 Cr | - | 593.60 Cr | 620.80 Cr | 659.90 Cr | 410.90 Cr |
| Tax Provision | 66.96 Cr | 83.00 Cr | 103.40 Cr | 65.66 Cr | - | 129.20 Cr | 110.80 Cr | 163.70 Cr | 94.20 Cr |
| Net Income | 305.00 Cr | 332.00 Cr | 412.00 Cr | 405.00 Cr | - | 464.40 Cr | 510.00 Cr | 496.20 Cr | 316.70 Cr |
| Diluted EPS | 7.64 | 8.29 | 10.30 | 10.12 | 9.82 | 11.51 | 12.69 | 12.34 | 7.87 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 3,189.00 Cr | 3,704.00 Cr | 4,163.00 Cr | 4,883.00 Cr | - | 5,831.00 Cr | 6,151.60 Cr | 6,795.90 Cr | 7,054.70 Cr |
| Current Assets | - | - | - | - | - | 2,425.30 Cr | 1,959.00 Cr | 2,287.30 Cr | 2,142.80 Cr |
| Cash & Equivalents | - | - | - | - | - | 87.00 Cr | 85.60 Cr | 366.90 Cr | 228.60 Cr |
| Inventory | - | - | - | - | - | 332.80 Cr | 238.50 Cr | 155.50 Cr | 141.30 Cr |
| Receivables | - | - | - | - | - | 529.30 Cr | 441.60 Cr | 526.80 Cr | 508.80 Cr |
| Total Liabilities | - | - | - | - | - | 2,213.00 Cr | 1,893.90 Cr | 2,069.00 Cr | 2,215.70 Cr |
| Current Liabilities | - | - | - | - | - | 1,188.20 Cr | 1,144.30 Cr | 1,396.40 Cr | 1,552.30 Cr |
| Long Term Debt | - | - | - | - | 531.50 Cr | 489.00 Cr | 100.00 Cr | 0 | - |
| Total Debt | 787.00 Cr | 813.00 Cr | 773.00 Cr | 893.00 Cr | - | 815.20 Cr | 555.20 Cr | 577.90 Cr | 458.40 Cr |
| Total Equity | 1,720.00 Cr | 1,968.00 Cr | 2,176.00 Cr | 2,821.00 Cr | - | 3,618.00 Cr | 4,257.70 Cr | 4,726.90 Cr | 4,839.00 Cr |
| Shares Outstanding | - | - | - | - | - | 40.14 Cr | 40.20 Cr | 40.25 Cr | 40.29 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 446.00 Cr | 630.00 Cr | 677.00 Cr | 701.00 Cr | - | 823.50 Cr | 1,042.10 Cr | 1,167.60 Cr | 915.20 Cr |
| Investing Cash Flow | -349.00 Cr | -646.00 Cr | -424.00 Cr | -629.00 Cr | - | -656.40 Cr | -495.60 Cr | -744.70 Cr | -860.40 Cr |
| Financing Cash Flow | -79.00 Cr | -72.00 Cr | -226.00 Cr | 58.00 Cr | - | -342.50 Cr | -551.40 Cr | -141.80 Cr | -215.00 Cr |
| Capital Expenditure | -364.00 Cr | -583.00 Cr | -643.00 Cr | -446.00 Cr | - | -518.30 Cr | -510.80 Cr | -770.10 Cr | -368.20 Cr |
| Free Cash Flow | 82.00 Cr | 47.00 Cr | 34.00 Cr | 255.00 Cr | - | 305.20 Cr | 531.30 Cr | 397.50 Cr | 547.00 Cr |
| Net Change in Cash | 18.00 Cr | -88.00 Cr | 28.00 Cr | 130.00 Cr | - | -175.40 Cr | -4.90 Cr | 281.10 Cr | -160.20 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 72.1% | 72.4% | 73.2% | 74.6% |
| Operating Margin % | 24.1% | 20.4% | 19.8% | 18.5% | - | 20.1% | 19.2% | 17.5% | 15.4% |
| Net Margin % | 21.4% | 18.2% | 20.5% | 18.5% | - | 15.1% | 15.1% | 14.1% | 8.8% |
| ROE % | 17.7% | 16.9% | 18.9% | 14.4% | - | 12.8% | 12.0% | 10.5% | 6.5% |
| ROCE % | - | - | - | - | - | 13.3% | 12.9% | 11.4% | 10.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SYNGENE
Syngene International Shares Slide 8% After Q1 Swings To Loss, Revenue Misses Estimates - NDTV Profit
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNN1NxZnFpMS05YVYwMEhNZ19QVFNiS1NhMWxvNGdXRVc1T244LU5PTWRQdXpVenFlU2p5a1JrUE5QcWQwT2ZIWTlDSmxWQmRuR1V3VG9Fczg5bU9ucEtQVW9sMno1Z3gyemZuaUJKbmpNN3BCZ1k2U3V2LVl3aHRIU18wUzV2bEg2UklSQm…
Syngene International Limited Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxObmNiNmVfdTBDeVYzWklhdFdBdGxyYm0xYmpMMWJlSW9hc0I5Yl92ZUQxdXE3WlJUekp3Nk54T1VDX3FHSnUxY0hKdDg1RWFvYzEwMGxIM01CWkVtVkxoVjZfVGhkSU1DZllocWR4V1ZRZ1RDTEdMUy1na0ZyWEk1OHVWUk94cWg5OWZVUU…
Volumes spurt at Syngene International Ltd counter - Business Standard
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxONWFWeXdjOW5YV3V5S2JacE1ZNlN4QXRtdXpmazlOdXR4c0JNbDZNdWc3RkE5ejVyekVOTHc1TnRQb0RyUHczQnh6Y3VHdEhiQ2hDZTRjbDA1NnJJaS05eE00SDdrbGxrV1BkOWcyNEVQaTRoWjBMRktvanJrZ0puN0FHS3NPUmpLYWRrNi…
Syngene International gets ₹8.62 Cr refund for AY 2014-15 - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxORm1SOE9fWko5YUJ2aTlJTFpwRkxuQktlZEM0WHlNZjRZeFl1dmowc0p4UGd6bXdWVjlsZkpxU1BtUzRrVjJ1UDdZeGJFaVlCdXczeFA3ZEo4Yml0WjdoeDJPSmg4WGxyR1pVY1N3eE1vUWpXeExOZmdNMUdDQzdVQjg1SUxBSk40UmZTTD…
Syngene Q1 FY27 slides: revenue drops 16%, margins contract sharply - Investing.com
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQbXIzRlJTZTNzb3pLTlgxX1c0QlhmdGJoeThjRHNCVi1SUlNxQU0zdmZjNW4yaGdub1UwNkFxUVJPcTN3b1otTEZ1RUZYZjhyVzZtOVlvdzBsX1hNbWRHckZ0UW5sbkdNQkZYQUJPcHdMUTUtWUplRzZIVURMV2szVDctUmFHTlhVVkFvMU…
Weeks after Otsuka license, Biodexa secures MTX240 trial manufacturing - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTDBzX2JNQlNGV0tQekVEZDkzZks1OG1XQmhIVE5aWVdPNVhQSHlZTDZGLW4wZVJyNXNrRmtzUjFQX1NoTDNaZUc2WjlTZGNlNWg0UlhLRlNCYnNqQ2tFTUZILUFrNlJMSXNjdmEtMUx6YU9yV04wVFI2dWFoT09henNWVktTZjAzZktKQW…
SYNGENE — Frequently Asked Questions
What is the current share price of Syngene International Limited (SYNGENE)?
As of 2026-09-08 04:53 IST, Syngene International Limited (SYNGENE) trades at ₹395.60 on NSE. Its 52-week range is ₹385.90 to ₹681.12.
What is the market capitalisation of SYNGENE?
Syngene International Limited (SYNGENE) has a market capitalisation of ₹15,940.28 Cr on NSE.
What is the P/E ratio of SYNGENE?
SYNGENE trades at a trailing price-to-earnings (P/E) ratio of 50.27. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 3.35.
Does SYNGENE pay a dividend?
Syngene International Limited (SYNGENE) currently offers a dividend yield of 0.31%.
What is the return on equity (ROE) of SYNGENE?
SYNGENE has a return on equity (ROE) of 6.54%. Its return on capital employed (ROCE) is 8.28%.
Is SYNGENE a good stock to buy?
This page provides a data-driven analysis of Syngene International Limited (SYNGENE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.